Exelixis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are eleven US patents protecting EXELIXIS drugs.
There are two hundred and seven patent family members on EXELIXIS drugs in thirty-two countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Exelixis
| International Patents: | 207 |
| US Patents: | 11 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
| Patent Litigation for Exelixis: | See patent lawsuits for Exelixis |
Drugs and US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | Yes | 9,717,720 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 9,724,342 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | 8,497,284 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | Yes | 11,091,439 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | 8,497,284 | ⤷ Sign Up |
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | 8,497,284 | ⤷ Sign Up |
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | 8,497,284 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Exelixis Drugs
Supplementary Protection Certificates for Exelixis Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 122014000091 | Germany | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321 |
| 2213661 | 132014902289810 | Italy | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB(COMETRIQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/890/001,002,003, 20140326 |
| 2213661 | SPC/GB14/052 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/13/890/001-006 20140326 |
| 2213661 | 43/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326 |
| 2213661 | PA2014033 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
